{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
m cidofovir
to a specific field?
Class (Stereo):
CHEMICAL (MIXED)
Etanterol (VAL 481), a phenethanolamine derivative, is a β2 adrenoceptor agonist that was undergoing phase II trials in Italy as a bronchodilator with Valeas.
Status:
Investigational
Class (Stereo):
CHEMICAL (ABSOLUTE)
IRDABISANT is a histamine H3 receptor inverse agonist with potential therapeutic utility in cognition enhancement.
Status:
Class (Stereo):
CHEMICAL (ACHIRAL)
ISOMETAMIDIUM (as a chloride salt) is widely used in tropical countries as an antiprotozoal agent to control animal trypanosomiasis. It is used principally in cattle but also in sheep, goats, buffalos, donkeys, horses, camels and dogs.
Class (Stereo):
CHEMICAL (RACEMIC)
Oxoprostol was developed as a gastric acid secretion inhibitor. Information about the further development of this drug is not available.
Class (Stereo):
CHEMICAL (RACEMIC)
Loviride (R 89439) is a non-nucleoside inhibitor of reverse transcriptase. It inhibits virion and recombinant reverse transcriptase of HIV-1. It was being studied in the combination therapy of HIV infection with other anti-HIV agents.
Class (Stereo):
CHEMICAL (RACEMIC)
Axitirome (also known as CGS 26214), a thyroid hormone receptor β selective agonist and an LDL receptor function stimulant, has a cholesterol-lowering activity. This drug was in phase I clinical trials for the treatment of hyperlipidemia, but studies were discontinued because of the unexpected side effects.
Class (Stereo):
CHEMICAL (ACHIRAL)
Morpheridine is a pethidine analog with strong analgesic activity. Morpheridine does not cause convulsions, although it produces the standard opioid side effects such as sedation and respiratory depression. Morpheridine is not currently used in medicine and is a Schedule I drug which is controlled under United Nations drug conventions.
Status:
Investigational
Source:
NCT00003914: Phase 2 Interventional Completed Kidney Cancer
(1999)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Dolastatin 10 is an unusual peptide of marine origin which binds to tubulin, inhibits microtubule assembly, resulting in the formation of tubulin aggregates and inhibition of mitosis. Dolastatin 10 has been used in trials phase II studying the treatment of Sarcoma, Leukemia, Lymphoma, Liver Cancer, among others. In case of hormone-refractory prostate cancer, it lacks significant clinical activity as a single agent and also dolastatin-10 is inactive against hepatobiliary and pancreatic carcinomas.
Status:
Investigational
Source:
INN:lancovutide [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
LANCOVUTIDE, also known as duramycin, is a 19-amino-acid tetracyclic peptide antibiotic. It is in clinical development for the treatment of cystic fibrosis (CF). It activates an alternative chloride channel in lung epithelial cells by elevating intracellular calcium levels, and may potentially compensate for CF transmembrane conductance regulator deficiency in the airway epithelium and increase the volume of the airway surface liquid.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Cethromycin is a ketolide antibiotic derived from erythromycin A being investigated for use in community-acquired pneumonia and other respiratory tract infections. Cethromycin possesses reliable activity against the bacteria most commonly associated with community-acquired pneumonia including S. pneumoniae, H. influenzae, M. catarrhalis, M. pneumoniae, C. pneumoniae, and L. pneumophila. Unlike fluoroquinolones, cethromycin has a narrower spectrum of activity against gram-negative bacteria, which may reduce the risk of collateral damage and the incidence of Clostridium difficile infection. It offers an advantage over telithromycin in that hepatotoxicity does not seem to be a concern. The FDA denied approval of cethromycin for the treatment of CAP in 2009, requesting more efficacy data.
